Life-saving role of heart attack centres confirmed in new study
14 Nov 2012
Recent studies questioning the role of specialist heart attack centres have produced misleading results because doctors tend to send the sickest patients to have the best care, reveals new research.
Many heart attack patients in the UK are sent to a specialist centre for primary angioplasty - a surgical procedure to reopen the blocked artery. Randomised trials have found that angioplasty is much more successful than drug treatment alone, but research based on "real-world" data suggest that patients given an angioplasty don't tend to do better.
Now researchers at Imperial College London have shown that the apparent lack of benefit in the clinical records is due to high-risk patients being more likely to be sent to a heart attack centre, which skews the data. After taking this bias is into account, they find that primary angioplasty reduces the death rate from heart attacks by 22 per cent.
They say the findings confirm that heart attack centres play a vital role, and should be made available more widely. The latest figures show that 82 per cent of heart attack patients in England and 30 per cent in Wales receive a primary angioplasty, with wide discrepancies in access between regions.
"There has been some debate in the cardiology community about whether it is worthwhile to run specialist heart attack centres, despite evidence from clinical trials that they save lives," says, Dr Iqbal Malik, one of the study's authors, from the National Heart and Lung Institute at Imperial . "This study resolves an important question. We must strive to make sure everyone in the UK has access to the best emergency treatment in the event of a heart attack."
The findings are published today in Circulation Cardiovascular Quality and Outcomes. The authors warn that in real life, doctors faced with a very sick patient tend to give them the most effective possible treatment. This phenomenon - termed allocation bias - is good medical practice but can make "comparative effectiveness" research unreliable. Adjusting for this bias is difficult because doctors may base their decisions on many features that are difficult to document. The Imperial team developed a method to help other researchers detect when a disease is vulnerable to this form of bias in evaluation of its treatments.
